Institute for Psycholinguistics and Digital Health, United States of America.
Department of Psychiatry, NYU Grossman School of Medicine, United States of America.
J Affect Disord. 2022 Oct 1;314:59-67. doi: 10.1016/j.jad.2022.07.004. Epub 2022 Jul 6.
At-home Ketamine-assisted therapy (KAT) with psychosocial support and remote monitoring through telehealth platforms addresses access barriers, including the COVID-19 pandemic. Large-scale evaluation of this approach is needed for questions regarding safety and effectiveness for depression and anxiety.
In this prospective study, a large outpatient sample received KAT over four weeks through a telehealth provider. Symptoms were assessed using the Patient Health Questionnaire (PHQ-9) for depression, and the Generalized Anxiety Disorder scale (GAD-7) for anxiety. Demographics, adverse events, and patient-reported dissociation were also analyzed. Symptom trajectories were identified using Growth Mixture Modeling, along with outcome predictors.
A sample of 1247 completed treatment with sufficient data, 62.8 % reported a 50 % or greater improvement on the PHQ-9, d = 1.61, and 62.9 % on the GAD-7, d = 1.56. Remission rates were 32.6 % for PHQ-9 and 31.3 % for GAD-7, with 0.9 % deteriorating on the PHQ-9, and 0.6 % on the GAD-7. Four patients left treatment early due to side effects or clinician disqualification, and two more due to adverse events. Three patient subpopulations emerged, characterized by Improvement (79.3 %), Chronic (11.4 %), and Delayed Improvement (9.3 %) for PHQ-9 and GAD-7. Endorsing side effects at Session 2 was associated with delayed symptom improvement, and Chronic patients were more likely than the other two groups to report dissociation at Session 4.
At-home KAT response and remission rates indicated rapid and significant antidepressant and anxiolytic effects. Rates were consistent with laboratory- and clinic-administered ketamine treatment. Patient screening and remote monitoring maintained low levels of adverse events. Future research should assess durability of effects.
通过远程医疗平台提供的家庭氯胺酮辅助治疗(KAT)与心理社会支持结合,可解决包括 COVID-19 大流行在内的诸多获得性障碍。对于这种方法在治疗抑郁和焦虑方面的安全性和有效性问题,需要进行大规模评估。
在这项前瞻性研究中,一个大型的门诊样本通过远程医疗提供商接受了为期四周的 KAT 治疗。使用患者健康问卷(PHQ-9)评估抑郁症状,使用广泛性焦虑症量表(GAD-7)评估焦虑症状。还分析了人口统计学资料、不良事件和患者报告的分离情况。使用增长混合建模来识别症状轨迹,以及预测结果。
1247 名完成治疗且数据充足的患者样本中,有 62.8%报告 PHQ-9 改善了 50%或更多,d 值为 1.61,GAD-7 改善了 62.9%,d 值为 1.56。PHQ-9 的缓解率为 32.6%,GAD-7 的缓解率为 31.3%,PHQ-9 恶化率为 0.9%,GAD-7 恶化率为 0.6%。有 4 名患者因副作用或临床医生不合格而提前退出治疗,另有 2 名患者因不良事件而提前退出治疗。对于 PHQ-9 和 GAD-7,出现了三个患者亚群,特征分别为改善(79.3%)、慢性(11.4%)和延迟改善(9.3%)。第 2 次治疗时报告副作用与症状延迟改善相关,慢性患者比其他两组更有可能在第 4 次治疗时报告分离。
家庭 KAT 的反应和缓解率表明了快速而显著的抗抑郁和抗焦虑作用。这些结果与实验室和临床管理的氯胺酮治疗一致。患者筛查和远程监测保持了低水平的不良事件。未来的研究应该评估疗效的持久性。